Pembrolizumab + CVA21 in Advanced NSCLC

NCT02824965 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Pembrolizumab
BIOLOGICAL: CVA21

Sponsor

Olivia Newton-John Cancer Research Institute

Collaborators

[object Object]
[object Object]